Pharma Mar (PHMMF)
(Delayed Data from OTC)
$26.85 USD
0.00 (0.00%)
Updated Apr 15, 2024 12:19 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Pharma Mar falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 171 | 207 | 272 | 308 | 96 |
Cost Of Goods | NA | 14 | 19 | 16 | 6 |
Gross Profit | NA | 193 | 252 | 293 | 90 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 146 | 143 | 115 | 110 |
Income After Depreciation & Amortization | 0 | 46 | 109 | 178 | -20 |
Non-Operating Income | NA | 12 | 12 | 6 | 0 |
Interest Expense | NA | 12 | 9 | 18 | 5 |
Pretax Income | NA | 46 | 113 | 166 | -24 |
Income Taxes | NA | -6 | 3 | 10 | -14 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1 | 52 | 110 | 157 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | -2 |
Net Income (GAAP) | 1 | 52 | 110 | 157 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 53 | 116 | 186 | -13 |
Depreciation & Amortization (Cash Flow) | NA | 6 | 7 | 8 | 7 |
Income After Depreciation & Amortization | 0 | 46 | 109 | 178 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.92 | 18.06 | 18.09 | 18.33 | 18.43 |
Diluted EPS Before Non-Recurring Items | 0.07 | 2.88 | 6.07 | 8.56 | -0.48 |
Diluted Net EPS (GAAP) | 0.07 | 2.88 | 6.07 | 8.56 | -0.67 |
Fiscal Year end for Pharma Mar falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 36.47 |
Cost Of Goods | NA | NA | NA | NA | 2.29 |
Gross Profit | NA | NA | NA | NA | 34.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 36.95 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -2.76 |
Non-Operating Income | NA | NA | NA | NA | 0.00 |
Interest Expense | NA | NA | NA | NA | 0.69 |
Pretax Income | NA | NA | NA | NA | -3.45 |
Income Taxes | NA | NA | NA | NA | -4.97 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | 1.51 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | 1.51 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |